- Home
- PHAT vs EYPT Comparison
PHAT vs EYPT Comparison
Compare PHAT & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHAT
- EYPT
- Stock Information
- Founded
- PHAT 2018
- EYPT 1987
- Country
- PHAT United States
- EYPT United States
- Employees
- PHAT N/A
- EYPT N/A
- Industry
- PHAT Biotechnology: Pharmaceutical Preparations
- EYPT Biotechnology: Laboratory Analytical Instruments
- Sector
- PHAT Health Care
- EYPT Industrials
- Exchange
- PHAT Nasdaq
- EYPT Nasdaq
- Market Cap
- PHAT 769.0M
- EYPT 741.0M
- IPO Year
- PHAT 2019
- EYPT 2005
- Fundamental
- Price
- PHAT $11.70
- EYPT $13.98
- Analyst Decision
- PHAT Strong Buy
- EYPT Strong Buy
- Analyst Count
- PHAT 5
- EYPT 6
- Target Price
- PHAT $16.40
- EYPT $25.83
- AVG Volume (30 Days)
- PHAT 1.3M
- EYPT 1.1M
- Earning Date
- PHAT 11-06-2025
- EYPT 11-06-2025
- Dividend Yield
- PHAT N/A
- EYPT N/A
- EPS Growth
- PHAT N/A
- EYPT N/A
- EPS
- PHAT N/A
- EYPT N/A
- Revenue
- PHAT $114,039,000.00
- EYPT $51,898,000.00
- Revenue This Year
- PHAT $213.11
- EYPT N/A
- Revenue Next Year
- PHAT $91.84
- EYPT N/A
- P/E Ratio
- PHAT N/A
- EYPT N/A
- Revenue Growth
- PHAT 1049.82
- EYPT 2.99
- 52 Week Low
- PHAT $2.21
- EYPT $3.91
- 52 Week High
- PHAT $19.50
- EYPT $14.91
- Technical
- Relative Strength Index (RSI)
- PHAT 50.37
- EYPT 58.55
- Support Level
- PHAT $10.33
- EYPT $13.00
- Resistance Level
- PHAT $12.97
- EYPT $14.04
- Average True Range (ATR)
- PHAT 0.89
- EYPT 0.93
- MACD
- PHAT -0.11
- EYPT -0.08
- Stochastic Oscillator
- PHAT 45.41
- EYPT 60.34
About PHAT Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.
About EYPT EyePoint Pharmaceuticals Inc.
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.